Erlmeier, F.;                     Sun, N.;                     Shen, J.;                     Feuchtinger, A.;                     Buck, A.;                     Prade, V.M.;                     Kunzke, T.;                     Schraml, P.;                     Moch, H.;                     Autenrieth, M.;     
    et al.    MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas. Cancers 2022, 14, 1763.
    https://doi.org/10.3390/cancers14071763
    AMA Style
    
                                Erlmeier F,                                 Sun N,                                 Shen J,                                 Feuchtinger A,                                 Buck A,                                 Prade VM,                                 Kunzke T,                                 Schraml P,                                 Moch H,                                 Autenrieth M,         
        et al.        MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas. Cancers. 2022; 14(7):1763.
        https://doi.org/10.3390/cancers14071763
    
    Chicago/Turabian Style
    
                                Erlmeier, Franziska,                                 Na Sun,                                 Jian Shen,                                 Annette Feuchtinger,                                 Achim Buck,                                 Verena M. Prade,                                 Thomas Kunzke,                                 Peter Schraml,                                 Holger Moch,                                 Michael Autenrieth,         
         and et al.        2022. "MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas" Cancers 14, no. 7: 1763.
        https://doi.org/10.3390/cancers14071763
    
    APA Style
    
                                Erlmeier, F.,                                 Sun, N.,                                 Shen, J.,                                 Feuchtinger, A.,                                 Buck, A.,                                 Prade, V. M.,                                 Kunzke, T.,                                 Schraml, P.,                                 Moch, H.,                                 Autenrieth, M.,                                 Weichert, W.,                                 Hartmann, A.,                                 & Walch, A.        
        
        (2022). MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas. Cancers, 14(7), 1763.
        https://doi.org/10.3390/cancers14071763